Is Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Worth Much? What Should Investors Do? – Marketing Sentinel
Home  »  Science   »  Is Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Wort...

Is Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Worth Much? What Should Investors Do?

During the last session, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)’s traded shares were 0.49 million, with the beta value of the company hitting 1.06. At the end of the trading day, the stock’s price was $1.04, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the CRVS share is $9.54, that puts it down -817.31 from that peak though still a striking 1.92% gain since the share price plummeted to a 52-week low of $1.02. The company’s market capitalization is $50.69M, and the average intraday trading volume over the past 10 days was 0.24 million shares, and the average trade volume was 248.28K shares over the past three months.

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) trade information

Corvus Pharmaceuticals Inc. (CRVS) registered a 0.00% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet 0.00% in intraday trading to $1.04 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -18.11%, and it has moved by -30.20% in 30 days. Based on these gigs, the overall price performance for the year is -58.40%. The short interest in Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) is 0.34 million shares and it means that shorts have 1 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Corvus Pharmaceuticals Inc. (CRVS) estimates and forecasts

Statistics show that Corvus Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Corvus Pharmaceuticals Inc. (CRVS) shares have gone down -76.52% during the last six months, with a year-to-date growth rate more than the industry average at 17.48% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -120.70% this quarter and then jump 55.90% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.20%. While earnings are projected to return -408.00% in 2022.

CRVS Dividends

Corvus Pharmaceuticals Inc. is due to release its next quarterly earnings between March 23 and March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)’s Major holders

Corvus Pharmaceuticals Inc. insiders own 3.56% of total outstanding shares while institutional holders control 59.97%, with the float percentage being 62.18%. Orbimed Advisors LLC. is the largest shareholder of the company, while 77 institutions own stock in it. As of Dec 30, 2021, the company held over 6.94 million shares (or 14.92% of all shares), a total value of $16.73 million in shares.

The next largest institutional holding, with 3.28 million shares, is of Adams Street Partners, LLC’s that is approximately 7.04% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $7.89 million.

Also, the Mutual Funds coming in first place with the largest holdings of Corvus Pharmaceuticals Inc. (CRVS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.82 million shares. This amounts to just over 1.76 percent of the company’s overall shares, with a $1.97 million market value. The same data shows that the other fund manager holds slightly less at 0.35 million, or about 0.75% of the stock, which is worth about $0.84 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts